Table Graph
   

potential COVID-19 treatments - versus control - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.96 [0.92, 1.00]< 10%8 studies (8/-)97.2 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.75 [0.43, 1.31]< 118%2 studies (2/-)84.3 %lownot evaluable highcrucial-
deaths 0.95 [0.90, 1.00]< 12%12 studies (12/-)97.5 %some concernlow moderatecrucial1
deaths (time to event analysis only) 0.56 [0.38, 0.84]< 10%2 studies (2/-)99.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.12 [0.62, 2.03]< 10%3 studies (3/-)35.5 %lownot evaluable highimportant-
clinical improvement 1.21 [1.08, 1.36]> 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.31 [0.61, 2.83]> 10%2 studies (2/-)75.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.35 [1.03, 1.76]> 10%1 study (1/-)98.7 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.24 [1.10, 1.41]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.90 [0.81, 0.99]< 10%2 studies (2/-)98.2 %some concernnot evaluable moderateimportant-
hospital discharge 0.64 [0.37, 1.11]> 10%1 study (1/-)5.6 %NAnot evaluable important-
hospitalization 0.77 [0.14, 4.08]< 182%2 studies (2/-)62.1 %lownot evaluable highimportant-
mechanical ventilation 1.00 [0.72, 1.40]< 117%4 studies (4/-)49.2 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.69 [0.14, 3.42]< 10%1 study (1/-)67.5 %NAnot evaluable important-
viral clearance 1.16 [0.53, 2.53]> 149%3 studies (3/-)64.1 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.29 [0.61, 2.74]> 159%2 studies (2/-)75.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.18 [0.01, 4.75]> 10%1 study (1/-)15.7 %NAnot evaluable important-
viral clearance by day 7 0.58 [0.14, 2.48]> 10%1 study (1/-)23.3 %NAnot evaluable important-
ICU admission 0.92 [0.43, 1.99]< 10%3 studies (3/-)58.3 %some concernnot evaluable moderatenon important-
recovery 1.18 [0.87, 1.61]> 10%1 study (1/-)85.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.05 [0.59, 1.86]< 162%3 studies (3/-)43.3 %some concernnot evaluable moderateimportant-
adverse events 0.88 [0.48, 1.60]< 10%2 studies (2/-)66.2 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.64 [0.23, 1.81]< 10%1 study (1/-)80.0 %NAnot evaluable non important-
elevated liver enzymes 0.67 [0.38, 1.18]< 10%1 study (1/-)91.8 %NAnot evaluable non important-
hyperbilirubinemia 0.84 [0.30, 2.34]< 10%1 study (1/-)62.9 %NAnot evaluable non important-
pulmonary embolism 0.96 [0.19, 4.80]< 10%1 study (1/-)51.7 %NAnot evaluable non important-
renal impairment 1.02 [0.64, 1.61]< 10%1 study (1/-)47.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons